🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the fight against superbug strains of the pathogen, according to health experts.

A Global Public Health Issue

Cases of gonorrhoea are on the rise around the world, with estimates suggesting over 82 million infections each year. Particularly high rates are seen in the African continent and nations within the WHO's designated area, which spans from China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune step in the face of increasing worldwide cases, escalating drug resistance and the highly restricted treatment choices at this time.”

Health officials are deeply concerned about the surge in drug-resistant strains. The World Health Organization has designated it as a "high-priority threat". Recent surveillance revealed that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Secure Clearance

One new antibiotic, also known as a brand name, was authorized by the US FDA in recent days for combating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Experts hope that focused deployment of this new drug will help delay the spread of drug resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, also received approval in the same week. This medication, which is also used to treat UTIs, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to see it through.

“This approval marks a major breakthrough in the management of highly resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Research Study Outcomes and Global Access

According to data published in a prominent scientific publication, zoliflodacin cured more than 90% of uncomplicated infections. This places it at an similar efficacy with the current standard treatment, which involves an injection and a pill. The research enrolled hundreds of participants from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, GARDP has the ability to make available and distribute the drug in numerous regions with limited resources.

Doctors on the front lines have shared positive views. Having a easy-to-administer therapy of this kind is hailed as a "critical tool" for managing the epidemic. This is viewed as essential to reduce the burden of the infection for patients and to prevent the spread of extremely resistant gonorrhoea globally.